BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29269252)

  • 1. Factors associated with nonadherence to instructions for using the Nestorone®/ethinyl estradiol contraceptive vaginal ring.
    Stifani BM; Plagianos M; Vieira CS; Merkatz RB
    Contraception; 2018 May; 97(5):415-421. PubMed ID: 29269252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acceptability of the Nestorone®/ethinyl estradiol contraceptive vaginal ring: development of a model; implications for introduction.
    Merkatz RB; Plagianos M; Hoskin E; Cooney M; Hewett PC; Mensch BS
    Contraception; 2014 Nov; 90(5):514-21. PubMed ID: 24993487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of concurrent vaginal miconazole treatment on the absorption and exposure of Nestorone® (segesterone acetate) and ethinyl estradiol delivered from a contraceptive vaginal ring: a randomized, crossover drug-drug interaction study.
    Simmons KB; Kumar N; Plagianos M; Roberts K; Hoskin E; Han L; Alami M; Creasy G; Variano B; Merkatz R
    Contraception; 2018 Mar; 97(3):270-276. PubMed ID: 29097225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact on hepatic estrogen-sensitive proteins by a 1-year contraceptive vaginal ring delivering Nestorone® and ethinyl estradiol.
    Archer DF; Thomas MA; Conard J; Merkatz RB; Creasy GW; Roberts K; Plagianos M; Blithe D; Sitruk-Ware R
    Contraception; 2016 Jan; 93(1):58-64. PubMed ID: 26408374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol.
    Weisberg E; Fraser IS; Mishell DR; Lacarra M; Darney P; Jackanicz TM
    Contraception; 1999 May; 59(5):305-10. PubMed ID: 10494484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen.
    Fraser IS; Weisberg E; Brache V; Alvarez F; Massai R; Mishell DR; Apter D; Gale J; Tsong YY; Sivin I
    Contraception; 2005 Jul; 72(1):40-5. PubMed ID: 15964291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study.
    Jensen JT; Edelman AB; Chen BA; Archer DF; Barnhart KT; Thomas MA; Burke AE; Westhoff CL; Wan LS; Sitruk-Ware R; Kumar N; Variano B; Blithe DL
    Contraception; 2018 May; 97(5):422-427. PubMed ID: 29409834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical performance and menstrual bleeding patterns with three dosage combinations of a Nestorone progestogen/ethinyl estradiol contraceptive vaginal ring used on a bleeding-signaled regimen.
    Weisberg E; Brache V; Alvarez F; Massai R; Mishell DR; Apter D; Gale J; Sivin I; Tsong YY; Fraser IS
    Contraception; 2005 Jul; 72(1):46-52. PubMed ID: 15964292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring.
    Weisberg E; Fraser IS; Lacarra M; Mishell DR; Alvarez F; Brache V; Nash HA
    Contraception; 1999 May; 59(5):311-8. PubMed ID: 10494485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
    Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
    Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaginal epithelial surface appearances in women using vaginal rings for contraception.
    Fraser IS; Lacarra M; Mishell DR; Alvarez F; Brache V; Lähteenmäki P; Elomaa K; Weisberg E; Nash HA
    Contraception; 2000 Feb; 61(2):131-8. PubMed ID: 10802278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased impact of a contraceptive vaginal ring with ethinyl estradiol and nestorone on C-reactive protein.
    Rad M; Burggraaf J; Sitruk-Ware RL; de Kam ML; Cohen AF; Kluft C
    Steroids; 2012 Nov; 77(13):1483-6. PubMed ID: 22982353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A technology evaluation of Annovera: a segesterone acetate and ethinyl estradiol vaginal ring used to prevent pregnancy for up to one year.
    Micks EA; Jensen JT
    Expert Opin Drug Deliv; 2020 Jun; 17(6):743-752. PubMed ID: 32410464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone turnover markers in women participating in a dose-finding trial of a contraceptive vaginal ring releasing Nestorone and estradiol.
    Tiedeken M; Westhoff CL; Cohen A; Cremers S; Sitruk-Ware R; Blithe DL;
    Contraception; 2019 Jun; 99(6):329-334. PubMed ID: 30871934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of different insertion regimens on side effects with a combination contraceptive vaginal ring.
    Weisberg E; Fraser IS; Lacarra M; Mishell DR; Jackanicz T
    Contraception; 1997 Oct; 56(4):233-9. PubMed ID: 9408704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for and outcomes of ring expulsions with a 1-year contraceptive vaginal system.
    Plagianos MG; Ramanadhan S; Merkatz RB; Brache V; Friedland BA; Haddad LB
    Am J Obstet Gynecol; 2024 May; 230(5):548.e1-548.e8. PubMed ID: 38295968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables.
    Rad M; Kluft C; Ménard J; Burggraaf J; de Kam ML; Meijer P; Sivin I; Sitruk-Ware RL
    Am J Obstet Gynecol; 2006 Jul; 195(1):72-7. PubMed ID: 16545330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control and lipid profiles.
    Alvarez-Sanchez F; Brache V; Jackanicz T; Faundes A
    Contraception; 1992 Oct; 46(4):387-98. PubMed ID: 1486777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contraceptive vaginal ring containing segesterone acetate and ethinyl estradiol: long-acting, patient-controlled, procedure-free, reversible prescription birth control.
    Paton DM
    Drugs Today (Barc); 2019 Jul; 55(7):449-457. PubMed ID: 31347613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility study of Nestorone-ethinylestradiol vaginal contraceptive ring for emergency contraception.
    Croxatto HB; Brache V; Massai R; Alvarez F; Forcelledo ML; Pavez M; Cochon L; Salvatierra AM; Faundes A
    Contraception; 2006 Jan; 73(1):46-52. PubMed ID: 16371294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.